Conference Reports for NATAP

Back

51th ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL September 17-20, 2011     Comparison of Population Genotype and Ultradeep Sequencing Results from Subjects with Virologic Failure in ARIES: Impact of Low-abundance HIV Variants on Outcome - (10/10/11)   Pre-Therapy Detection of Transmitted Low-abundance HIV-1 Resistance Mutation-containing Variants in Antiviral-naïve Subjects and Implications for Subsequent Clinical Therapy Response - (10/10/11)   Significant Reductions in the Prevalence of Protease Inhibitor and 3-Class Resistance: Recent Trends in a Large HIV-1 Protease/Reverse Transcriptase Database - (10/08/11)   Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients - (10/08/11)   Kidney Function Change With Cobicistat Calculated in HIV-Negative Volunteers - Written by Mark Mascolini - (09/30/11)   Intracellular Raltegravir Concentrations Better With Twice-Daily Than Once-Daily Dosing - Written by Mark Mascolini - (09/30/11)   TMC435 in combination with peginterferon and ribavirin for treatment of HCV genotype 1 infection: Week 24 interim analyses of Phase IIB PILLAR and ASPIRE trials - (09/30/11)   HAART Treatment Interruption Following Adoptive Transfer of Zinc Finger Nuclease (ZFN) CCR5 Modified AutologousCD4 T-cells (SB-728-T) to HIV-infected Subjects Demonstrates Durable Engraftment and Suppression of Viral Load - (09/29/11)   ICAAC 2011: Medically Important Highlights - David H Shepp, MD, Hofstra NSLIJ Medical School Division of Infectious Diseases North Shore University Hospital - Manhasset- (09/29/11)   51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) September 17-20, 2011 Chicago, IL - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA (09/29/11)   Responder-relapser (RR) patients might obtain benefit in liver fibrosis, after anti-HCV chemotherapy, in comparison to non-responders (NR) or non-treated (control) HIV- HCV coinfected patients - (09/27/11)   Longitudinal assessment of liver fibrosis (LF) by non-invasive methods in HIV- HCV coinfected patients, after HCV chemotherapy - (09/27/11)   Dolutegravir vs Resistant Mutants: Selective Advantage Profiles of HIV-1 Integrase Mutants in the Presence of Dolutegravir - (09/26/11)   Liver Stiffness (LS) change in HIV/Hepatitis C (HCV) co-infected patients treated with CCR5 inhibitor based antiretroviral Therapy - (09/26/11)   Under 10% in Large Canadian Cohort Reach Normal CD4/CD8 Ratio - (09/26/11)   An Open-Label, Placebo-controlled Study to Evaluate the Effect of Dolutegravir (DTG, S/GSK1349572) on Iohexol and Para-aminohippurate Clearance in Healthy Subjects - Written by Mark Mascolini - (09/26/11)   Dolutegravir & Creatinine Clearance - Written by Mark Mascolini - (09/26/11)   Pharmacokinetic analysis of nevirapine extended release 400 mg QD vs immediate release 200 mg BID in patients with HIV-1 infection - (09/24/11)   Nevirapine Concentrations With Once- Versus Twice-Daily Dosing - Written by Mark Mascolini - (09/24/11)   Fosamprenavir/RTV Cuts Dolutegravir Levels: No Dose Change Needed for Naive - Written by Mark Mascolini - (09/24/11)   HCV and Homocysteine Boost Risk of Covert Atherosclerosis in Spanish HIV Group - Written by Mark Mascolini - (09/24/11)   Novel Boehringer-Ingelheim Integrase Inhibitor Retains Full Activity Against Raltegravir-Resistant Virus - Written by Mark Mascolini - (09/24/11)   Effect of Fosamprenavir/Ritonavir on the Pharmacokinetics of the Integrase Inhibitor, Dolutegravir, in Healthy Subjects - (09/24/11)   Safety, Tolerability, and Efficacy of Raltegravir (RAL) in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study - (09/22/11)   Merck's ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race - (09/21/11)   Durable and Consistent Efficacy of Raltegravir (RAL) With Tenofovir (TDF) and Emtricitabine (FTC) Across Demographic and Baseline Prognostic Factors In Treatment-naïve Patients (pts) From STARTMRK at Wk 156 - (09/22/11)   Rilpivirine (TMC278) tolerability over the first 12 weeks of treatmentin the Phase III ECHO and THRIVE studies - (09/22/11)   Adoptive Transfer of Zinc Finger Nuclease CCR5 Modified Autologous CD4 T-cells (SB-728-T) to Aviremic HIV-infected Subjects with Suboptimal CD4 Counts (200-500 cells/mm3) - (09/22/11)   Safety, Efficacy, and Pharmacokinetics of Ibalizumab in Treatment-Experienced HIV-1 Infected Patients: a Phase 2b Study - (09/22/11)   Recruiting Young LA Gays for HIV Survey by Social-Networking App - Written by Mark Mascolini (09/21/11)   ART-HCV Protease Inhibitor BI-201335 Interactions - (09/21/11)   Sangamo HIV Gene Therapy Data Reported at ICAAC Sept 19 2011 - (09/21/11)   The Pharmacokinetic Interaction Between Telaprevir & Raltegravir in Healthy Volunteers - (09/21/11)   (New BI Integrase Inhibitor) Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers - (09/21/11)   BI 224436, a Non-Catalytic Site Integrase Inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1 - (09/21/11)   Pharmacodynamics of BI 224436 for HIV-1 in an in vitro hollow fiber infection model system - (09/21/11)   Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic Site Integrase Inhibitor - (09/21/11)   Effect of Cobicistat on Glomerular Filtration Rate in Subjects with Normal and Impaired Renal Function - (09/21/11)   HIV Risk Perception Does Not Match PrEP Interest in US Heterosexual Group - (09/21/11)   Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort - (09/21/11)   Rate of Stopping Atripla for Side Effects Steady Through 96 Weeks in London Cohort - (09/21/11)   Randomized Switch From Suppressive PI to Etravirine Safe and Effective - (09/21/11)   Insulin Resistance Quadruples Liver Cancer Risk in People With HIV/HCV - (09/21/11)   Switching From TDF/FTC to Raltegravir Improves Kidney Markers - (09/21/11)   Higher Osteoprotegerin Linked to Lower Atherosclerosis Risk in Men With HIV - (09/21/11)   Switching From Atripla to Complera Safe and Effective in 12-Week Study - (09/21/11)   Risk of Neurosyphilis With Early Syphilis in German Group With HIV - (09/21/11)   PHA Better Than PLA for HIV Facial Atrophy at 96 Weeks, But More Painful - (09/21/11)   High Rates of SVR24 for BMS-790052, an NS5A Replication Complex Inhibitor, in Combination With PegIFN-alfa-2a and Ribavirin: Phase 2a Trial in Treatment-Naive HCV Genotype 1 Subjects - (09/19/11)   BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients - (09/19/11)   Better 1-Month Safety With Rilpivirine Than Efavirenz in Treatment-Naive - (09/19/11)   Switching from Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV-1 Infected Subjects - (09/19/11)   Detection of Baseline Resistance and HIV RNA Suppression to Week 48 in the SENSE Trial: Etravirine versus Efavirenz in Treatment Naïve Participants - (09/19/11)   PI and 3-Class Resistance Drop Sharply in Monogram Database: 2003-2010 - Written by Mark Mascolini - (09/19/11)   "Ultradeep" Detection of Pretreatment Mutations Has Little Impact on Long-Term PI (Reyataz/r) Response - Written by Mark Mascolini - (09/19/11)   One Penicillin Dose as Good as Three for Early Syphilis in Men With HIV - Written by Mark Mascolini - (09/19/11)   Adding Maraviroc May Reduce Liver Stiffness in People With HCV and HIV - Written by Mark Mascolini - (09/19/11)   Some Lipids Improve With Switch From ABC/3TC to TDF/FTC, HIV Control Rates Similar - Written by Mark Mascolini - (09/19/11)   Resistance Rates and Patterns Similar With Extended- and Immediate-Release Nevirapine - Written by Mark Mascolini - (09/19/11)   Hospital Rate Lower With Atripla Than Other Combos in Medicaid Patients - Written by Mark Mascolini - (09/19/11)   Delayed HIV Care Persists in Chicago Minorities Years After CDC Screening Advice - Written by Mark Mascolini - (09/19/11)   Chicago Hospital Study Finds 11+ HIV Prescribing Errors Per 100 Patient-Days - Written by Mark Mascolini - (09/19/11)   Gender or Race Does Not Affect Raltegravir Response in Diverse Group - Written by Mark Mascolini - (09/19/11)   Dropping Inactive NRTI Does Not Compromise 4- or 5-Drug Salvage Combos - Written by Mark Mascolini - (09/19/11)   "Selective Advantage" Analysis Sees Low Risk of Cross-Resistance With Dolutegravir - Written by Mark Mascolini - (09/19/11)   Zinc Finger-Modified CD4-Cell Booster Transplant Working in Pilot Trial - Written by Mark Mascolini - (09/19/11)   Pretreatment Mutations Do Not Affect Etravirine or Efavirenz Response in SENSE - Written by Mark Mascolini - (09/19/11)   Large Sample Analysis Confirms Impact of Known Rilpivirine Mutations - Written by Mark Mascolini - (09/19/11)